Summary
137.29 -5.21(-3.65%)07/26/2024
DaVita Inc (DVA)
DaVita Inc (DVA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.65 | -0.48 | -3.44 | 2.70 | 28.06 | 35.67 | 131.13 | 3,269.15 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 137.29 | |
| Open | 143.39 | |
| High | 143.79 | |
| Low | 136.30 | |
| Volume | 718,357 | |
| Change | -5.21 | |
| Change % | -3.65 | |
| Avg Volume (20 Days) | 528,483 | |
| Volume/Avg Volume (20 Days) Ratio | 1.36 | |
| 52 Week Range | 71.51 - 147.93 | |
| Price vs 52 Week High | -7.19% | |
| Price vs 52 Week Low | 91.99% | |
| Range | -4.25 | |
| Gap Up/Down | -1.98 | |
Fundamentals | ||
| Market Capitalization (Mln) | 12,051 | |
| EBIDTA | 2,492,648,960 | |
| PE Ratio | 15.5918 | |
| PEG Ratio | 1.1642 | |
| WallStreet Target Price | 142.93 | |
| Book Value | 10.5580 | |
| Earnings Per Share | 8.8200 | |
| EPS Estimate Current Quarter | 1.9500 | |
| EPS Estimate Next Quarter | 2.5000 | |
| EPS Estimate Current Year | 9.5700 | |
| EPS Estimate Next Year | 10.1600 | |
| Diluted EPS (TTM) | 8.8200 | |
| Revenues | ||
| Profit Marging | 0.0661 | |
| Operating Marging (TTM) | 0.1440 | |
| Return on asset (TTM) | 0.0636 | |
| Return on equity (TTM) | 0.4322 | |
| Revenue TTM | 12,338,002,944 | |
| Revenue per share TTM | 136.9220 | |
| Quarterly Revenue Growth (YOY) | 0.0690 | |
| Quarterly Earnings Growth (YOY) | 1.1200 | |
| Gross Profit (TTM) | 3,400,341,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 15.5918 | |
| Forward PE | 14.1844 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 10.7830 | |
| Revenue Enterprise Value | 1.8214 | |
| EBITDA Enterprise Value | 9.5268 | |
| Shares | ||
| Shares Outstanding | 87,702,600 | |
| Shares Float | 48,028,028 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.07 | |
| Insider (%) | 45.16 | |
| Institutions (%) | 50.96 | |
07/22 19:21 EST - zacks.com
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
The latest trading day saw DaVita HealthCare (DVA) settling at $139.96, representing a +1.46% change from its previous close.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
The latest trading day saw DaVita HealthCare (DVA) settling at $139.96, representing a +1.46% change from its previous close.
07/18 14:00 EST - prnewswire.com
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
DENVER , July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time.
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
DENVER , July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time.
07/16 19:05 EST - zacks.com
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
DaVita HealthCare (DVA) reachead $137.72 at the closing of the latest trading day, reflecting a +1.3% change compared to its last close.
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
DaVita HealthCare (DVA) reachead $137.72 at the closing of the latest trading day, reflecting a +1.3% change compared to its last close.
07/16 13:16 EST - zacks.com
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
07/16 10:20 EST - globenewswire.com
Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 with a Remarkable 37.2% CAGR, According to Straits Research
Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032 Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032
Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 with a Remarkable 37.2% CAGR, According to Straits Research
Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032 Renal Denervation Devices Market Size, Share & Trends Analysis Report By Technology (Radiofrequency-based, Ultrasound-based, Micro-infusion-based, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032
07/13 09:16 EST - reuters.com
US FTC probing DaVita, Fresenius Medical, Politico reports
The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
US FTC probing DaVita, Fresenius Medical, Politico reports
The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
07/12 07:11 EST - zacks.com
Here's Why You Should Add DaVita (DVA) to Your Portfolio
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
07/10 10:41 EST - zacks.com
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
07/09 19:20 EST - zacks.com
DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing
DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.
DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing
DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.
07/04 08:30 EST - zacks.com
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
06/26 19:20 EST - zacks.com
DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.
DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.
06/26 10:45 EST - zacks.com
Are Medical Stocks Lagging DaVita (DVA) This Year?
Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging DaVita (DVA) This Year?
Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
06/24 10:46 EST - zacks.com
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
06/24 10:46 EST - zacks.com
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy DaVita (DVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
06/20 19:21 EST - zacks.com
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.
06/17 10:51 EST - zacks.com
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
06/15 05:45 EST - fool.com
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid
One stock in Buffett's Berkshire Hathaway portfolio continues to grow its profits by leaps and bounds. Another ranks among his top performers in 2024 and is poised for growth, thanks to acquisitions.
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid
One stock in Buffett's Berkshire Hathaway portfolio continues to grow its profits by leaps and bounds. Another ranks among his top performers in 2024 and is poised for growth, thanks to acquisitions.
06/13 19:12 EST - zacks.com
DaVita HealthCare (DVA) Stock Declines While Market Improves: Some Information for Investors
DaVita HealthCare (DVA) reachead $142.16 at the closing of the latest trading day, reflecting a -0.37% change compared to its last close.
DaVita HealthCare (DVA) Stock Declines While Market Improves: Some Information for Investors
DaVita HealthCare (DVA) reachead $142.16 at the closing of the latest trading day, reflecting a -0.37% change compared to its last close.
06/13 09:47 EST - zacks.com
3 PEG-Based Value Picks to Boost Your Portfolio Returns
Invest in shares of Eldorado Gold (EGO), Sasol (SSL) and DaVita (DVA) that hold huge upside potential.
3 PEG-Based Value Picks to Boost Your Portfolio Returns
Invest in shares of Eldorado Gold (EGO), Sasol (SSL) and DaVita (DVA) that hold huge upside potential.
06/13 09:02 EST - zacks.com
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.